Table 2 Role of the modifier in cancer
Type of cancer | Role of the modifier | m6A(methylation) modifier |
|---|---|---|
Breast cancer | Oncogene | METTL5, WTAP, VIRMA, ZNF217, FTO, ALKBH5, ELAVL1, YTHDF1/2/3, IGF2BP1/2/3, HNRNPs |
Tumor suppressor | ZC3H13, HAKAI | |
Bivalent | METTL3/14 | |
Lung Cancer | Oncogene | METTL3/5, WTAP, VIRMA, HAKAI, FTO, ELAVL1, YTHDF1, IGF2BP1/3, HNRNPs |
Tumor suppressor | METTL14, YTHDC2 | |
Bivalent | ALKBH5, YTHDF2, IGF2BP2 | |
Prostate cancer | Oncogene | VIRMA, ZNF217, ELAVL1, YTHDF2, IGF2BP2, HNRNPs |
Tumor suppressor | FTO | |
Bivalent | METTL3 | |
Colorectal cancer | Oncogene | WTAP, ZNF217, HAKAI, ELAVL1, YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3, HNRNPs, FTO |
Tumor suppressor | METTL14, ZC3H13 | |
Bivalent | METTL3, ALKNH5 | |
Gastric cancer | Oncogene | METTL3/16, WTAP, VIRMA, ZNF217, ALKBH5, ELAVL1, YTHDF1, IGF2BP1/2/3, HNRNPs |
Tumor suppressor | METTL14, YTHDF2 | |
Bivalent | FTO | |
Liver cancer | Oncogene | METTL3, WTAP, VIRMA, ZNF217, FTO, YTHDF1/3, YTHDC2, IGF2BP1/2/3, HNRNPs |
Tumor suppressor | METTL14 | |
Bivalent | ALKBH5, ELAVL1, YTHDF2 | |
Cervical cancer/ endometrial cancer/ ovarian cancer | Oncogene | ZNF217, WTAP, FTO, ALKBH5, YTHDF1, IGF2BP1/2/3, HNRNPs, ELAVL1, YTHDF2 |
Bivalent | METTL3, YTHDF2 | |
Esophageal cancer | Oncogene | METTL3, WTAP, FTO, ELAVL1, IGF2BP1/2/3, HNRNPs |
Bivalent | ALKBH5 | |
Thyroid cancer | Oncogene | METTL14, IGF2BP1/2/3 |
Tumor suppressor | FTO | |
Bivalent | METTL3 | |
Bladder cancer | Oncogene | METTL3, WTAP, YTHDF2, IGF2BP1 |
Tumor suppressor | METTL14, ALKBH5 | |
Bivalent | FTO | |
Pancreatic cancer | Oncogene | METTL3/14, WTAP, YTHDF2, IGF2BP2/3, HNRNPs |
Tumor suppressor | FTO, ALKBH5, YTHDC1 | |
Leukaemia | Oncogene | METTL3/14, WTAP, FTO, ALKBH5, YTHDF2, IGF2BP1/2/3, RBM15 |
Kidney cancer | Oncogene | WTAP, IGF2BP1/3, HNRNPs |
Tumor suppressor | METTL14, FTO, YTHDF2 | |
Bivalent | ALKBH5 | |
Melanoma | Oncogene | METTL3, FTO, ALKBH5, ELAVL1, YTHDF1/2, IGF2BP1/2/3, HNRNPs |
Head and neck cancer | Oncogene | METTL3, FTO, ALKBH5, ELAVL1, YTHDF1, IGF2BP1/2//3, HNRNPs |
Bivalent | YTHDC2 | |
Glioblastoma | Oncogene | METTL3, ZNF217, ALKBH5, ELAVL1, YTHDF1/2, IGF2BP1/2/3 |
Osteosarcoma | Oncogene | METTL14, ZNF217, ELAVL1, IGF2BP1 |
Tumor suppressor | YTHDF2 | |
Bivalent | ALKBH5 | |
Cholangiocarcinoma/ gallbladder cancer | Oncogene | IGF2BP1/2 |
Tumor suppressor | FTO, ALKBH5 | |
Retinoblastoma | Oncogene | METTL3, IGF2BP1 |
lymphomas | Oncogene | METTL3/14, WTAP, RBM15, FTO, ALKBH5, YTHDF2, IGF2BP1/2/3 |
Rhabdomyosarcoma | Oncogene | IGF2BP1 |
Seminoma | Oncogene | METTL3 |
Thymic epithelial cancer | Oncogene | METTL3 |